We found that our model generally predicted the correct trends for both immunoglobulins, e.g., downtrend in IgA in response to treatment, and biomarkers related to CRAB (Hypercalcemia, Renal failure, Anemia, and Bone lesions) complications (e.g., calcium, hemoglobin, and creatinine). This evidence concerns the gene CD79A and kidney failure.